29 Aug 2018 10:13
29 August 2018
SINCLAIR PHARMA PLC
RE AGREEMENT WITH HUADONG MEDICINE AESTHETICS INVESTMENT (HONGKONG) LIMITED
London, 29 August 2018 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, notes the RNS announcement (No. 0469Z) by Huadong Medicine at 16:41 on 28 August 2018. A copy of the announcement is available on the Group's website.
For further information please contact:
Sinclair Pharma plc | Tel: +44 (0) 20 7467 6920 |
Grahame Cook Chris Spooner Alan Olby Andy Crane |
|
Rothschild (Lead Financial Adviser to Sinclair) | Tel: +44 (0)20 7280 5000 |
Dominic Hollamby Julian Hudson |
|
Peel Hunt (Joint Financial Adviser, Nominated Adviser and Joint Broker to Sinclair) James Steel Michael Nicholson Oliver Jackson | Tel: +44 (0)20 7418 8900 |
Notes to Editors:
About Sinclair Pharma plc - www.sinclairpharma.com
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. The Group has recently established a direct presence in the US.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.